Aprogen Biologics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 20,133.63 million compared to KRW 16,016.33 million a year ago. Net loss was KRW 4,859.47 million compared to net income of KRW 4,473.33 million a year ago. Basic loss per share from continuing operations was KRW 70 compared to basic earnings per share from continuing operations of KRW 110 a year ago. Diluted loss per share from continuing operations was KRW 70 compared to diluted earnings per share from continuing operations of KRW 110 a year ago. Basic loss per share was KRW 70 compared to basic earnings per share of KRW 110 a year ago.
For the nine months, sales was KRW 941.16 million compared to KRW 37.99 million a year ago. Net loss was KRW 21,469.44 million compared to net income of KRW 10,391.56 million a year ago. Basic loss per share from continuing operations was KRW 350 compared to basic earnings per share from continuing operations of KRW 260 a year ago. Diluted loss per share from continuing operations was KRW 350 compared to diluted earnings per share from continuing operations of KRW 260 a year ago. Basic loss per share was KRW 350 compared to basic earnings per share of KRW 260 a year ago.